Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance

Nature Genetics

Volumn 48, Issue 5, 2016, Pages 544-551

  Desjardins, Christopher A ^a   Cohen, Keira A ^a,b,c   Munsamy, Vanisha ^c   Abeel, Thomas ^a,d   Maharaj, Kashmeel ^c   Walker, Bruce J ^a   Shea, Terrance P ^a   Almeida, Deepak V ^c,e   Manson, Abigail L ^a   Salazar, Alex ^a,d   Padayatchi, Nesri ^f   O'Donnell, Max R ^f,g,h   Mlisana, Koleka P ^i,j   Wortman, Jennifer ^a   Birren, Bruce W ^a   Grosset, Jacques ^c,e   Earl, Ashlee M ^a   Pym, Alexander S ^c  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^d DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF KWAZULU NATAL   (South Africa)

^g College of Physicians and Surgeons ^*  (United States)

^h Columbia Mailman School of Public Health ^*  (United States)

ⁱ UNIVERSITY OF KWAZULU NATAL   (South Africa)

^j NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE DEHYDROGENASE; CYCLOSERINE; ALANINE RACEMASE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; CONVERGENT EVOLUTION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; IN VITRO STUDY; LOSS OF FUNCTION MUTATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NONSENSE MUTATION; PRIORITY JOURNAL; BACTERIAL GENOME; DRUG EFFECTS; ENZYMOLOGY; GENE INACTIVATION; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MUTATION;

ALANINE DEHYDROGENASE; ALANINE RACEMASE; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; CYCLOSERINE; DRUG RESISTANCE, BACTERIAL; GENE KNOCKOUT TECHNIQUES; GENOME, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS;

EID: 84964833030     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3548     Document Type: Article

References (65)

1. Bauer K.A, Perez K.K, Forrest G.N, & Goff D.A. Review of rapid diagnostic tests used by antimicrobial stewardship programs. Clin. Infect. Dis. 59 (suppl. 3), S134-S145 (2014).
2. Boehme C.C, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 363, 1005-1015 (2010).
3. Kiet V.S, et al. Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 48, 2934-2939 (2010).
4. Bastos M.L, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- And second-line drugs: an individual patient data meta-Analysis. Clin. Infect. Dis. 59, 1364-1374 (2014).
5. Cegielski J.P, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin. Infect. Dis. 59, 1049-1063 (2014).
6. Lange C, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur. Respir. J. 44, 23-63 (2014).
7. Theron G, et al. The diagnostic accuracy of the GenoType(®) MTBDRsl assay for the detection of resistance to second-line anti-Tuberculosis drugs. Cochrane Database Syst. Rev. 10, CD010705 (2014).
8. Finegold S.M. Kanamycin. AMA Arch. Intern. Med. 104, 15-28 (1959).
9. Murray F.J. A PILOT study of cycloserine toxicity; a United States Public Health Service Cooperative Clinical Investigation. Am. Rev. Tuberc. 74, 196-209 (1956).
10. Bankier R.G. Psychosis associated with cycloserine. Can. Med. Assoc. J. 93, 35-37 (1965).
11. Boston Collaborative Drug Surveillance Program. Drug-induced deafness. JAMA. 224, 515-516 (1973).
12. Yew W.W, Wong C.F, Wong P.C, Lee J, & Chau C.H. Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin. Clin. Infect. Dis. 17, 288-289 (1993).
13. Woods G.L. Susceptibility testing for mycobacteria. Clin. Infect. Dis. 31, 1209-1215 (2000).
14. Kam K.M, et al. Determination of critical concentrations of second-line anti-Tuberculosis drugs with clinical and microbiological relevance. Int. J. Tuberc. Lung Dis. 14, 282-288 (2010).
15. World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis (World Health Organization, 2014).
16. Lambert M.P, & Neuhaus F.C. Mechanism of d-cycloserine action: alanine racemase from Escherichia coli W. J. Bacteriol. 110, 978-987 (1972).
17. Strominger J.L, Ito E, & Threnn R.H. Competitive inhibition of enzymatic reactions by oxamycin. J. Am. Chem. Soc. 82, 998-999 (1960).
18. Prosser G.A, & de Carvalho L.P.S. Metabolomics reveal d-Alanine: d-Alanine ligase as the target of d-cycloserine in Mycobacterium tuberculosis. ACS Med. Chem. Lett. 4, 1233-1237 (2013).
19. Cáceres N.E, et al. Overexpression of the d-Alanine racemase gene confers resistance to d-cycloserine in Mycobacterium smegmatis. J. Bacteriol. 179, 5046-5055 (1997).
20. Feng Z, & Barletta R.G. Roles of Mycobacterium smegmatis d-Alanine: d-Alanine ligase and d-Alanine racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor d-cycloserine. Antimicrob. Agents Chemother. 47, 283-291 (2003).
21. Köser C.U, et al. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N. Engl. J. Med. 369, 290-292 (2013).
22. Merker M, et al. Whole genome sequencing reveals complex evolution patterns of multidrug-resistant Mycobacterium tuberculosis Beijing strains in patients. PLoS One 8, e82551 (2013).
23. Rist N, Canetti G, Boisvert H, & Le Lirzin M. The BCG antibiogram. Diagnostic value of resistance to cycloserine. Rev. Tuberc. Pneumol. (Paris). 31, 1060-1065 (1967).
24. Chen J.M, Uplekar S, Gordon S.V, & Cole S.T. A point mutation in cycA partially contributes to the d-cycloserine resistance trait of Mycobacterium bovis BCG vaccine strains. PLoS One 7, e43467 (2012).
25. Farhat M.R, et al. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat. Genet. 45, 1183-1189 (2013).
26. Zhang H, et al. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat. Genet. 45, 1255-1260 (2013).
27. Casali N, et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat. Genet. 46, 279-286 (2014).
28. Cohen K.A, et al. Evolution of extensively drug-resistant tuberculosis over four decades: whole genome sequencing and dating analysis of Mycobacterium tuberculosis isolates from KwaZulu-Natal. PLoS Med. 12, e1001880 (2015).
29. Wong S.Y, et al. Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55, 2515-2522 (2011).
30. Maus C.E, Plikaytis B.B, & Shinnick T.M. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49, 571-577 (2005).
31. Morlock G.P, Metchock B, Sikes D, Crawford J.T, & Cooksey R.C. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 47, 3799-3805 (2003).
32. Heym B, Alzari P.M, Honoré N, & Cole S.T. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol. Microbiol. 15, 235-245 (1995).
33. Scorpio A, & Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2, 662-667 (1996).
34. Pagel M. Detecting correlated evolution on phylogenies: a general method for the comparative analysis of discrete characters. Proc. R. Soc. Lond. B. 255, 37-45 (1994).
35. Lamichhane G, et al. A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA. 100, 7213-7218 (2003).
36. Li G, et al. Efflux pump gene expression in multidrug-resistant Mycobacterium tuberculosis clinical isolates. PLoS One 10, e0119013 (2015).
37. Converse S.E, et al. MmpL8 is required for sulfolipid-1 biosynthesis and Mycobacterium tuberculosis virulence. Proc. Natl. Acad. Sci. USA. 100, 6121-6126 (2003).
38. Reeves A.Z, et al. Aminoglycoside cross-resistance in Mycobacterium tuberculosis due to mutations in the 5' untranslated region of whiB7. Antimicrob. Agents Chemother. 57, 1857-1865 (2013).
39. Köser C.U, Bryant J.M, Parkhill J, & Peacock S.J. Consequences of whiB7 (Rv3197A) mutations in Beijing genotype isolates of the Mycobacterium tuberculosis complex. Antimicrob. Agents Chemother. 57, 3461 (2013).
40. Morris R.P, et al. Ancestral antibiotic resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA. 102, 12200-12205 (2005).
41. Warit S, et al. Genetic characterisation of a whiB7 mutant of a Mycobacterium tuberculosis clinical strain. J. Glob. Antimicrob. Resist. 3, 262-266 (2015).
42. Wiame J.M, & Piérard A. Occurrence of an l(+)-Alanine-dehydrogenase in Bacillus subtilis. Nature. 176, 1073-1075 (1955).
43. Department of Health, South Africa. Management of Drug-Resistant Tuberculosis: Policy Guidelines http://www.health-e.org.za/wp-content/uploads/2014/06/MDR-TB-Clinical-Guidelines-Updated-Jan-2013.pdf (2013).
44. Durek C, Rüsch-Gerdes S, Jocham D, & Böhle A. Sensitivity of BCG to modern antibiotics. Eur. Urol. 37 (suppl. 1), 21-25 (2000).
45. Goh K.S, & Rastogi N. Rapid preliminary differentiation of species within the Mycobacterium tuberculosis complex: proposition of a radiometric method. Res. Microbiol. 142, 659-665 (1991).
46. Garcia Pelayo M.C, et al. A comprehensive survey of single nucleotide polymorphisms (SNPs) across Mycobacterium bovis strains and M. bovis BCG vaccine strains refines the genealogy and defines a minimal set of SNPs that separate virulent M. bovis strains and M. bovis BCG strains. Infect. Immun. 77, 2230-2238 (2009).
47. Chen J.M, Alexander D.C, Behr M.A, & Liu J. Mycobacterium bovis BCG vaccines exhibit defects in alanine and serine catabolism. Infect. Immun. 71, 708-716 (2003).
48. Garnier T, et al. The complete genome sequence of Mycobacterium bovis. Proc. Natl. Acad. Sci. USA. 100, 7877-7882 (2003).
49. Sassetti C.M, Boyd D.H, & Rubin E.J. Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol. 48, 77-84 (2003).
50. Choi Y, Sims G.E, Murphy S, Miller J.R, & Chan A.P. Predicting the functional effect of amino acid substitutions and indels. PLoS One 7, e46688 (2012).
51. Falush D, & Bowden R. Genome-wide association mapping in bacteria? Trends Microbiol. 14, 353-355 (2006).
52. Shell S.S, et al. DNA methylation impacts gene expression and ensures hypoxic survival of Mycobacterium tuberculosis. PLoS Pathog. 9, e1003419 (2013).
53. Brosch R, et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc. Natl. Acad. Sci. USA. 99, 3684-3689 (2002).
54. Chavadi S, et al. Global effects of inactivation of the pyruvate kinase gene in the Mycobacterium tuberculosis complex. J. Bacteriol. 191, 7545-7553 (2009).
55. Keating L.A, et al. The pyruvate requirement of some members of the Mycobacterium tuberculosis complex is due to an inactive pyruvate kinase: implications for in vivo growth. Mol. Microbiol. 56, 163-174 (2005).
56. Ängeby K, Juréen P, Kahlmeter G, Hoffner S.E, & Schön T. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull. World Health Organ. 90, 693-698 (2012).
57. Torrea G, et al. Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system. J. Antimicrob. Chemother. 70, 2300-2305 (2015).
58. Kahlmeter G. The 2014 Garrod Lecture: EUCAST-Are we heading towards international agreement? J. Antimicrob. Chemother. 70, 2427-2439 (2015).
59. Pholwat S, et al. Integrated microfluidic card with TaqMan probes and high-resolution melt analysis to detect tuberculosis drug resistance mutations across 10 genes. MBio 6, e02273 (2015).
60. Benjamini Y, & Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B. 57, 289-300 (1995).
61. Li H, & Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 25, 1754-1760 (2009).
62. Walker B.J, et al. Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly improvement. PLoS One 9, e112963 (2014).
63. Price M.N, Dehal P.S, & Arkin A.P. FastTree 2-Approximately maximum-likelihood trees for large alignments. PLoS One 5, e9490 (2010).
64. George K.M, Yuan Y, Sherman D.R, & Barry C.E. III. The biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis. Identification and functional analysis of CMAS-2. J. Biol. Chem. 270, 27292-27298 (1995).
65. Streicher E.M, et al. Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility. J. Clin. Microbiol. 52, 4056-4057 (2014).